sunitinib / Pfizer, Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

25 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sunitinib / Generic mfg.
2007-005648-25: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique et intratumorale des molécules impliquées dans la voie VHL/HIF/VEGF.

Ongoing
3
100
Europe
Sunitinib, Sutent, Sutent
C.H.U. de RENNES
Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante
 
 
CheckMate 214, NCT02231749 / 2014-001750-42: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Checkmark Presentation of data from CheckMate 214 trial in advanced Sarcomatoid RCC at IKCS 2022
Nov 2022 - Nov 2022: Presentation of data from CheckMate 214 trial in advanced Sarcomatoid RCC at IKCS 2022
Checkmark Additional data following 42-month period in combination with Yervoy in advanced 1L RCC from CheckMate 214 study
Jan 2022 - Jan 2022: Additional data following 42-month period in combination with Yervoy in advanced 1L RCC from CheckMate 214 study
Checkmark Additional data following 42 month randomization from CheckMate-214 trial for advanced 1L RCC
More
Active, not recruiting
3
1390
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, Yervoy, Sunitinib, Sutent
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
06/17
08/27
KEYNOTE-679, NCT03260894 / 2017-002259-26: Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (/ECHO-302)

Active, not recruiting
3
129
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Epacadostat, INCB024360, Sunitinib, Sutent, SU11248, Pazopanib, Votrient
Incyte Corporation, Merck Sharp & Dohme LLC
Renal Cell Carcinoma (RCC)
08/18
12/24
KEYNOTE 426, NCT02853331 / 2016-000588-17: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Checkmark Long-term follow-up data from KEYNOTE-426 trial in combination with axitinib for RCC at ASCO 2021
Jun 2021 - Jun 2021: Long-term follow-up data from KEYNOTE-426 trial in combination with axitinib for RCC at ASCO 2021
Checkmark Long term follow-up data from KEYNOTE-426 trial in combination with Inlyta for RCC
May 2020 - May 2020: Long term follow-up data from KEYNOTE-426 trial in combination with Inlyta for RCC
Checkmark KEYNOTE-426 trial in combination with Inlyta in 1L advanced RCC at ASCO-GU 2019
More
Active, not recruiting
3
861
NA
Pembrolizumab, MK-3475, KEYTRUDA®, Axitinib, INLYTA®, Sunitinib, SUTENT®
Merck Sharp & Dohme LLC
Renal Cell Carcinoma
10/18
12/25
SAVOIR, NCT03091192 / 2016-004108-73: Savolitinib vs. Sunitinib in MET-driven PRCC.

Checkmark From SAVIOR trial vs sunitinib in patients with MET-driven papillary RCC
May 2020 - May 2020: From SAVIOR trial vs sunitinib in patients with MET-driven papillary RCC
Active, not recruiting
3
60
Europe, US, RoW
Savolitinib, AZD6094 (HMPL-504)/Volitinib, Sunitinib
AstraZeneca, Hutchinson MediPharma (HMP)
Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
08/19
12/24
CheckMate 9ER, NCT03141177 / 2017-000759-20: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Hourglass Jun 2023 - Jun 2023 : 3 year quality-of-life follow-up data from CheckMate -9ER trial in 1L RCC at ASCO 2023
Checkmark Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Jun 2022 - Jun 2022: Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Checkmark Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
Jun 2022 - Jun 2022: Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
More
Active, not recruiting
3
701
Europe, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Cabozantinib, Cabometyx, Sunitinib, Sutent, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb, Exelixis, Ono Pharmaceutical Co. Ltd
Renal Cell Carcinoma
02/20
04/24
CLEAR trial, NCT02811861 / 2016-000916-14: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Checkmark Presentation of data from CLEAR trial in advanced RCC at IKCS 2022
Nov 2022 - Nov 2022: Presentation of data from CLEAR trial in advanced RCC at IKCS 2022
Checkmark Data from CLEAR trial in combination with Lenvima for RCC at ESMO 2022
Sep 2022 - Sep 2022: Data from CLEAR trial in combination with Lenvima for RCC at ESMO 2022
Checkmark Data from CLEAR trial in combination with Lenvima for RCC at ASCO 2022
More
Active, not recruiting
3
1069
Europe, Canada, Japan, US, RoW
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Eisai Inc., Merck Sharp & Dohme LLC
Renal Cell Carcinoma
08/20
07/24
INTRIGUE, NCT03673501 / 2018-001803-35: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruiting
3
453
Europe, Canada, US, RoW
Ripretinib, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals LLC
Gastrointestinal Stromal Tumors
09/21
12/24
2021-000336-55: A clinical trial to compare the effectiveness of savolitinib plus durvalumab relative to sunitinib for the treatment of renal cell cancer.

Ongoing
3
200
Europe, RoW
Savolitinib, Durvalumab, AZD6094, HMPL-504, MEDI4736, Tablet, Concentrate for solution for infusion, Capsule, hard, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma, unresectable and locally advanced or metastatic renal cell cancer, Diseases [C] - Cancer [C04]
 
 
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Active, not recruiting
3
528
RoW
TQB2450, Anlotinib, Sunitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Renal Cancer
06/25
12/25
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Active, not recruiting
3
421
RoW
Biological : Toripalimab Drug: Axitinib, sunitinib
Shanghai Junshi Bioscience Co., Ltd.
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
06/23
06/23
JAVELIN Renal 101, NCT02684006 / 2015-002429-20: A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer

Checkmark Data from JAVELIN Renal 101 trial in combination with axitinib for IL RCC at ESMO 2019
Sep 2019 - Oct 2019: Data from JAVELIN Renal 101 trial in combination with axitinib for IL RCC at ESMO 2019
Checkmark JAVELIN Renal 101 trial in 1L mRCC
Feb 2019 - Feb 2019: JAVELIN Renal 101 trial in 1L mRCC
Checkmark Data presentation from JAVELIN Renal 101 trial in combination with Inlyta for 1L RCC at ESMO 2018
More
Completed
3
886
Europe, Canada, Japan, US, RoW
Avelumab (MSB0010718C), Axitinib (AG-013736), Inlyta, Sunitinib, Sutent
Pfizer
Renal Cell Cancer
08/23
06/24
NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Terminated
3
185
RoW
Famitinib capsules, Sunitinib Capsules, Sutent
Jiangsu HengRui Medicine Co., Ltd.
Gastrointestinal Stromal Tumors
03/22
03/22
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
SAMETA, NCT05043090: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Recruiting
3
220
Europe, Canada, US, RoW
savolitinib, AZD6094, HMPL-504, volitinib, durvalumab, MEDI4736, sunitinib, Sutent, SU11248
AstraZeneca
Papillary Renal Cell Carcinoma
06/25
06/26
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
PEAK, NCT05208047: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Recruiting
3
426
Europe, Canada, US, RoW
CGT9486 plus sunitinib, CGT9486, Sunitinib, sunitinib - Part 1b, sunitinib - Part 2
Cogent Biosciences, Inc.
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
07/25
09/26
STELLAR-304, NCT05678673: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Recruiting
3
291
Europe, US, RoW
XL092, Nivolumab, Opdivo®, Sunitinib Malate, Sutent®
Exelixis
Non-Clear Cell Renal Cell Carcinoma
07/25
06/28
INSIGHT, NCT05734105: A Study of Ripretinib Vs Sunitinib in Patients with Advanced GIST with Specific KIT Exon Mutations Who Were Previously Treated with Imatinib

Recruiting
3
54
Europe, Canada, US, RoW
Ripretinib, QINLOCK, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals, LLC
GIST
02/26
12/27
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
2016-001797-15: A trial testing an alternative high-dose, intermittend scheduling for sunitinib in patients with recurrent brain cancer Een onderzoek met hoge dosis sunitinib bij patiënten met terugkerende hersenkanker

Ongoing
2/3
100
Europe
Sunitinib, Lomustine, L01XE04, L01AD02, Capsule, Sutent, Belustine
VU University Medical Center, Department of Medical Oncology, VU University Medical Center, Deparment of Medical Oncology
- Glioblastoma multiforme (GBM) - Glioblastoma, - Brain cancer - Glioblastoma - Malignant Brain Tumor, Diseases [C] - Cancer [C04]
 
 
2017-000364-15: A trial testing TAS-102 therapy versus an alternative high-dose, intermittent scheduling for sunitinib in patients with metastatic colorectal carcinoma. Een onderzoek bij patiënten met uitgezaaid dikke darm en/of endeldarm kanker die een indicatie hebben voor behandeling met TAS-102 waarbij de behandeling met TAS-102 wordt vergeleken met een behandeling met hoge dosis, intermitterend, sunitinib.

Ongoing
2/3
60
Europe
sunitinib, L01XE04, Tablet, Sutent
VU University Medical Center, Department of Medical, VU University Medical Center, Department of Medical
Advanced colorectal tumors Gemetastaseerd colorectaal carcinoom, Metastasized (spread) or inoperable colorectal cancer Uitgezaaid (verspreid) of inoperabel colorectaal carcinoom, Diseases [C] - Cancer [C04]
 
 
SUNRISE-CRC, NCT03909724: Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Recruiting
2/3
60
Europe
Sunitinib Malate, Sutent, TAS 102, Lonsurf
Amsterdam UMC, location VUmc
Colorectal Cancer, Metastasis
07/21
07/22
STELLAR, NCT03025893: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

Recruiting
2/3
100
Europe
Sunitinib, Sutent, Lomustine, CCNU
Amsterdam UMC, location VUmc
Glioblastoma Multiforme, Glioblastoma, Adult, Glioblastoma, Recurrent Brain Tumor, GBM
01/22
01/22

Download Options